Esteemed oncologist Siddhartha Mukherjee has earned a place on the prestigious TIME100 Health 2026 list. His inclusion recognizes his significant contributions to medicine, particularly his recent work in leveraging artificial intelligence for pharmaceutical development.

Updating Foundational Cancer Knowledge

Mukherjee recently updated his seminal work on cancer, adding four new chapters to reflect recent advancements. These additions specifically address detection, prevention, treatment, and the overall comprehension of the disease.

He stated that he felt an “urgent need” to revise the material. This urgency stemmed from the substantial changes in oncological knowledge over recent years. Mukherjee believes this continuous learning is crucial for the medical community.

The Future of Cancer Treatment with AI

Looking ahead 15 years, Mukherjee anticipates that Artificial Intelligence will be central to creating new cancer treatments. He predicts these future therapies will be both more precise and significantly less costly.

This conviction led him to collaborate with LinkedIn co-founder Reid Hoffman last year. Together, they launched Manas AI, a startup dedicated to employing AI technology to accelerate drug discovery processes.

Manas AI's Breakthroughs in Drug Screening

Mukherjee highlighted the impressive capabilities demonstrated by their new venture. He noted that Manas AI has already discovered medicines with chemical compositions previously considered unimaginable.

The startup has made rapid progress in virtual screening. “Within six months, we have probably virtually screened or created virtual medicines that number in the hundreds of thousands, and we will get into the millions,” Mukherjee confirmed.

While only a small percentage of these virtual candidates will be synthesized into actual chemicals for testing against cancer cells, Mukherjee views these capabilities as a “massive turning point.” This technological leap provides substantial inspiration and potential for future cancer care.